Please login to the form below

Not currently logged in
Email:
Password:

Eisai wins EU licence for kidney cancer drug Kisplyx

Approved as a second-line combination treatment for advanced RCC
Eisai

The European Commission has approved Kisplyx (lenvatinib) for the treatment of adults with advanced renal cell carcinoma (RCC) after an accelerated assessment.

Eisai's breakthrough orally-active drug is licensed in combination with Novartis' mTOR inhibitor Afinitor (everolimus) in patients who have already been treated with at least one vascular endothelial growth factor (VEGF)-targeted therapy.

Its European approval is based on a phase II clinical trial showing the combination significantly extended progression-free survival in this patient population by 14.5 months, compared with the 5.5 months survival from Afinitor alone.

Under brand name Lenvima, Kisplyx was granted US marketing authorisation in May this year, the drug having received breakthrough and priority review status by the FDA.

Analysts are now suggesting that with Kisplyx's approval in two key markets, plus its current global availability as a thyroid cancer treatment, the drug has blockbuster potential.

The prospects for Eisai's drug over the coming years look particularly good, given RCC's status as the most common kidney cancer.

RCC accounts for 2-3% of all cancer diagnoses and affects around 58,000 people in the US and 115,000 in Europe every year, and is associated with a five-year survival rate of only 12%.

Gary Hendler, Eisai's chief commercial officer oncology business group, said: “This marketing authorisation underscores Eisai's ongoing commitment to delivering and developing advances in the fight against cancer.

“We remain committed to exploring the potential of lenvatinib for people with cancer, their family and carers.”

Article by
Rebecca Clifford

15th September 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics